全文获取类型
收费全文 | 264篇 |
免费 | 14篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 5篇 |
基础医学 | 28篇 |
口腔科学 | 1篇 |
临床医学 | 41篇 |
内科学 | 67篇 |
皮肤病学 | 4篇 |
神经病学 | 14篇 |
特种医学 | 4篇 |
外科学 | 35篇 |
综合类 | 6篇 |
预防医学 | 20篇 |
眼科学 | 18篇 |
药学 | 22篇 |
中国医学 | 3篇 |
肿瘤学 | 5篇 |
出版年
2023年 | 3篇 |
2022年 | 8篇 |
2021年 | 10篇 |
2020年 | 8篇 |
2019年 | 9篇 |
2018年 | 18篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 12篇 |
2014年 | 11篇 |
2013年 | 14篇 |
2012年 | 20篇 |
2011年 | 17篇 |
2010年 | 11篇 |
2009年 | 12篇 |
2008年 | 18篇 |
2007年 | 14篇 |
2006年 | 24篇 |
2005年 | 12篇 |
2004年 | 10篇 |
2003年 | 10篇 |
2002年 | 11篇 |
2001年 | 5篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1995年 | 1篇 |
1991年 | 1篇 |
排序方式: 共有278条查询结果,搜索用时 0 毫秒
31.
Javad Iskandarov George S. Fanourgakis Shehzad Ahmed Waleed Alameri George E. Froudakis Georgios N. Karanikolos 《RSC advances》2022,12(55):35703
Carbon dioxide foam injection is a promising enhanced oil recovery (EOR) method, being at the same time an efficient carbon storage technology. The strength of CO2 foam under reservoir conditions plays a crucial role in predicting the EOR and sequestration performance, yet, controlling the strength of the foam is challenging due to the complex physics of foams and their sensitivity to operational conditions and reservoir parameters. Data-driven approaches for complex fluids such as foams can be an alternative method to the time-consuming experimental and conventional modeling techniques, which often fail to accurately describe the effect of all important related parameters. In this study, machine learning (ML) models were constructed to predict the oil-free CO2 foam apparent viscosity in the bulk phase and sandstone formations. Based on previous experimental data on various operational and reservoir conditions, predictive models were developed by employing six ML algorithms. Among the applied algorithms, neural network algorithms provided the most precise predictions for bulk and porous media. The established models were then used to compute the critical foam quality under different conditions and determine the maximum apparent foam viscosity, effectively controlling CO2 mobility to co-optimize EOR and CO2 sequestration.Data-driven approaches for foams can be a time- and data-efficient alternative method to experimental and conventional modeling techniques. 相似文献
32.
33.
34.
35.
Amiodarone and the thyroid 总被引:4,自引:0,他引:4
Among the drugs affecting the thyroid gland, no drug has puzzled, and at the same time fascinated, endocrinologists more than amiodarone. Amiodarone is a potent class III anti-arrhythmic drug that also possesses beta-blocking properties. It is very rich in iodine, with a 100-mg tablet containing an amount of iodine that is 250 times the recommended daily iodine requirement. Amiodarone produces characteristic alterations in thyroid function tests in euthyroid patients. Understanding these alterations is crucial in avoiding unnecessary investigations and treatment. Amiodarone-induced thyroid dysfunction occurs because of both its iodine content and the direct toxic effects of the compound on thyroid parenchyma. Amiodarone-induced hyperthyroidism is more common in iodine-deficient regions of the world, whereas amiodarone-induced hypothyroidism is usually seen in iodine-sufficient areas. In contrast to amiodarone-induced hypothyroidism, amiodarone-induced thyrotoxicosis is a difficult condition to diagnose and treat. In this review, we discuss the alterations in thyroid function tests seen in euthyroid subjects, the epidemiology and mechanism of amiodarone-induced thyroid dysfunction, treatment options available, and the consequences of amiodarone use in pregnancy and lactation; and finally, we propose a follow-up strategy in patients taking amiodarone. 相似文献
36.
Xing M Westra WH Tufano RP Cohen Y Rosenbaum E Rhoden KJ Carson KA Vasko V Larin A Tallini G Tolaney S Holt EH Hui P Umbricht CB Basaria S Ewertz M Tufaro AP Califano JA Ringel MD Zeiger MA Sidransky D Ladenson PW 《The Journal of clinical endocrinology and metabolism》2005,90(12):6373-6379
CONTEXT: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer. OBJECTIVE: The objective of the study was to investigate the prognostic value of BRAF mutation in patients with PTC. DESIGN, SETTING, AND SUBJECTS: In a multicenter study of 219 PTC patients, data on their clinicopathological characteristics and clinical courses between 1990 and 2004 were retrospectively collected, and their tumor BRAF mutation status was determined. Associations of BRAF mutation with initial tumor characteristics and subsequent recurrence were analyzed. MAIN OUTCOME MEASURE: Relationships between the BRAF mutation status and clinicopathological outcomes, including recurrence, were measured. RESULTS: We found a significant association between BRAF mutation and extrathyroidal invasion (P < 0.001), lymph node metastasis (P < 0.001), and advanced tumor stage III/IV (P = 0.007) at initial surgery. This association remained significant on multivariate analysis, adjusting for conventional clinicopathological predictors of recurrence excluding the histological PTC subtype, but was lost when the tumor subtype was included in the model. BRAF mutation was also significantly associated with tumor recurrence, 25 vs. 9% with and without mutation, respectively (P = 0.004), during a median of 15 (interquartile range, 3-29) months of follow-up. This association remained significant on multivariate analysis adjusting for conventional clinicopathological predictors of recurrence, even including the PTC subtype (odds ratio, 4.0; 95% confidence interval, 1.1-14.1; P = 0.03). BRAF mutation was even an independent predictor of recurrence in patients with stage I/II disease, 22 vs. 5% with and without BRAF mutation, respectively (P = 0.002). BRAF mutation was also more frequently associated with absence of tumor I-131 avidity and treatment failure of recurrent disease. CONCLUSIONS: In patients with PTC, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence. Therefore, BRAF mutation may be a useful molecular marker to assist in risk stratification for patients with PTC. 相似文献
37.
Study Type – Preference (discrete choice experiment) Level of Evidence 2a What’s known on the subject? and What does the study add? Whilst antimuscarinic treatments are widely used little work has been done to understand how patients consider the relative benefits and costs associated with their use. This study provides data which demonstrates both the perceived value of symptom reduction and burden associated with common antimuscarinic AEs. These findings may prove useful in informing prescribing decisions. OBJECTIVE ? To examine patient preferences and strength of preferences for treatment for the various symptoms of overactive bladder and adverse events associated with the use of antimuscarinic treatments. PATIENTS AND METHODS ? A discrete choice experiment (DCE) survey was developed that detailed treatment choices in terms of attributes relating to their efficacy in reducing symptoms and the likelihood of experiencing typical adverse events. Levels for each attribute were based on a literature review, qualitative interviews and a meta‐analysis of clinical trial data. ? Attributes were combined into choice sets using a fractional orthogonal design that had been folded over. Pairs of choice sets were presented to overactive bladder (OAB) patients (n= 332), who indicated which treatment alternative they preferred. Data were analysed using the conditional logit model. RESULTS ? Participants expressed the strongest preference for the avoidance of urgency incontinence episodes, followed by preference for a reduction in the experience of urinary urgency and the number of micturition episodes. The influence of the likelihood of experiencing an adverse event on treatment preference was also estimated. ? Finally, marginal rates of substitution were calculated to demonstrate the relative value of trade‐offs between the various attributes. ? Treatment preferences were found to be broadly similar across two patient age groups (i.e. under 45 s and 45 and over). CONCLUSION ? The study demonstrates that individuals with OAB place significant emphasis on the prospect of reduction in symptoms. Avoidance of incontinence episodes is particularly valued and equivalent to a much greater reduction in the frequency of micturition or experience of urgency. However, even a modest increase in the likelihood of experiencing an adverse event could easily motivate a change in treatment preference. 相似文献
38.
39.
Maggio M Lauretani F Ceda GP Bandinelli S Basaria S Ble A Egan J Paolisso G Najjar S Jeffrey Metter E Valenti G Guralnik JM Ferrucci L 《Journal of the American Geriatrics Society》2006,54(12):1832-1838
OBJECTIVES: To determine whether low levels of testosterone, sex hormone binding globulin (SHBG), insulin-like growth factor-1 (IGF-1), and dehydroepiandrosterone sulfate (DHEAS) and high levels of cortisol and leptin would be associated with metabolic syndrome (MS). DESIGN: Cross-sectional. SETTING: Population-based sample of older Italian men. PARTICIPANTS: Four hundred fifty-two men aged 65 and older enrolled in the Invecchiare in Chianti (InCHIANTI) study. MEASUREMENTS: Complete data on testosterone, cortisol, DHEAS, SHBG, fasting insulin, IGF-1 and leptin. MS was defined according to Adult Treatment Panel III criteria. RESULTS: MS was present in 73 men (15.8% of the sample). After adjusting for confounders, total testosterone (P < .05) and log (SHBG) (P < .001) were inversely associated, whereas log (leptin) was positively associated with MS (P < .001). Independent of age, log (SHBG) was positively associated with high-density lipoprotein cholesterol (P < .05) and negatively associated with abdominal obesity (P < .001) and triglycerides (P < .001). Log (leptin) was significantly associated with each component of MS. Cortisol, DHEAS, free and bioavailable testosterone, and IGF-1 were not associated with MS. Having three or more hormones in the lower (for hormones lower in MS) or the upper (for hormones higher in MS) quartile was associated with three times the risk of being affected by MS (odds ratio = 2.8, 95% confidence interval = 1.3-6.9) (P = .005), compared with not having this condition. CONCLUSION: Total testosterone and SHBG are negatively and leptin is positively associated with MS in older men. Whether specific patterns of hormonal dysregulation predict the development of MS should be tested in longitudinal studies. 相似文献